


 Cite this: *RSC Adv.*, 2023, **13**, 7719

Propranolol induces large-scale remodeling of lipid bilayers: tubules, patches, and holes†

 Ni He and Tao Zhao *

Herein, we report fluorescence microscopy analysis of the interaction between propranolol (PPN), a beta-adrenergic blocking agent, and planar supported lipid bilayers (SLBs), as model membranes. The results indicate that PPN can remarkably promote largescale remodeling in SLBs with various lipid compositions. It was found that PPN insertion induces the formation of long microtubules that can retract into hemispherical caps on the surface of the bilayer. These transformations are dynamic, partially reversible, and dependent upon the drug concentration. Quantitative analysis revealed a three-step model for PPN–lipid bilayer interaction, with the first step involving interfacial electrostatic adsorption, the second step centered on hydrophobic insertion, and the third step associated with membrane disruption and hole formation. By introducing cholesterol, phosphoethanolamine, phosphatidylglycerol, and phosphatidylserine lipids into the phosphocholine SLBs, it was illustrated that both the chemistry of the lipid headgroups and the packing of lipid acyl chains can substantially affect the particular steps in the interactions between PPN and lipid bilayers. Our findings may help to elucidate the possible mechanisms of PPN interaction with lipid membranes, the toxic behavior and overdosage scenarios of beta-blockers, and provide valuable information for drug development and modification.

Received 16th January 2023

Accepted 1st March 2023

DOI: 10.1039/d3ra00319a

rsc.li/rsc-advances

Introduction

Currently, more than 60% of clinically important drugs target either integral or peripheral membrane-bound proteins, such as receptors and ion channels.¹ Meanwhile, drugs need to pass through one or more cell membranes to reach their targets of action. A great many studies have shown that membrane interactions can either result in better efficacy, selectivity and longer duration of action or cause undesirable toxicities through off-target interactions, reducing or even inhibiting the biological function of membrane proteins, and giving rise to possible serious cell damage.^{2,3} Therefore, it is of critical importance to understand the intrinsic influence of a drug on the lipid membrane in pharmacological science.^{4,5}

Propranolol (PPN) (Fig. 1a) is a beta-adrenergic blocking drug used in the treatment of several conditions, such as hypertension, angina pectoris, cardiac arrhythmias, myocardial infarction, anxiety disorders and migraine.⁶ It prevents binding of epinephrine and norepinephrine to cell surface receptors and inhibits intracellular signaling cascades.⁷ Extensive studies of PPN-membrane interactions have been made over the last

several decades, including the antihypertensive mechanism for this drug,^{8,9} its location within the lipid bilayer,^{10,11} and its influence on membrane physicochemical characteristics and the activity of membrane-bound enzymes.^{12–14} It has been reported that PPN is readily to interact with cellular membranes and induce functional alterations in a wide variety of membrane systems.^{14–18} For example, it was found that the addition of PPN can change membrane fluidity,¹⁹ membrane curvature,²⁰ as well as membrane elasticity and viscosity.²¹ Moreover, when the PPN concentration reached the mM range, it may lead to formation of PPN–lipid micelles and subsequently solubilization of the membrane.¹⁷ Although the effective concentration of PPN in the plasma at the proper dose of the drug is usually at μM range (about 0.03–600 μM),^{22–24} the peak concentrations of PPN in the cytoplasm are found up to 10–25 mM.^{7,25} Although it seems to be crucial for better understanding the mechanisms of drug action, systematic studies on PPN binding at lipid membrane interface over a wide range of concentrations is still lacking. Besides, in spite of qualitative insights into the interactions between PPN and lipid membranes, there is little information about the kinetics of membrane solubilization induced by PPN binding.^{19,20,26–29}

In the current study, we carried out fluorescence analysis to investigate the PPN (concentration range from μM to mM) interactions with supported lipid bilayers (SLBs), as model membranes. The SLBs were coated inside a polydimethylsiloxane (PDMS) well or a microfluidic device, allowing for various concentrations of PPN to be introduced over the

College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China. E-mail: zhaotao1982@126.com; Fax: +86-021-67791214

† Electronic supplementary information (ESI) available: Additional figures and movies. Movie S1, remodeling of POPC SLBs after 2.5 h incubation with 20 mM PPN. Movie S2, remodeling of POPC SLBs after 1.5 h incubation with 35 mM PPN. See DOI: <https://doi.org/10.1039/d3ra00319a>



Fluorescence microscopy

Fluorescent images were captured by Nikon Eclipse Ti-U inverted microscope (Tokyo, Japan) equipped with an Andor iKon-M 934 Back Illuminated CCD camera (Andor, Belfast, United Kingdom) and SHI-130 N1 (Nikon Yokohama, Japan) light source. A Texas Red filter set (Nikon, Tokyo, Japan) was used for imaging along with 4× (N.A. = 0.13), 10× (N.A. = 0.45×) and 40× air objectives (N.A. = 0.95). The NIS-Elements BR software (Nikon, Tokyo, Japan) was employed to process the fluorescent images.

Fluorescence recovery after photobleaching (FRAP)

The lateral diffusion of SLBs was determined by FRAP experiments.^{38–41} Herein, a 560 nm light beam (28 mm radius) was used to bleach the fluorescent probes within SLBs. Immediately after photobleaching, a series of images were captured and the fluorescence recovery ($F(t)$) was calculated using the following equation (eqn (1)):

$$F(t) = \frac{F_t - F_0}{1 - F_0} \quad (1)$$

where F_0 and F_t represent the normalized initial (at $t = 0$) and final (at time t) fluorescence intensities after photobleaching, respectively. The results were fit to a single exponential function (eqn (2)):

$$y = A(1 - e^{-kt}) \quad (2)$$

where A is the mobile fraction and k is the kinetic constant for the mobile fraction, which is used to calculate the half-time to recovery ($t_{1/2}$) (eqn (3)):

$$t_{1/2} = \frac{\ln(2)}{k} \quad (3)$$

Use $t_{1/2}$ to calculate the lateral diffusion coefficient (D) (eqn (4)):

$$D = \frac{\omega^2}{4t_{1/2}} \times \gamma \quad (4)$$

where ω is the radius of the fluorescent light beam, γ is the correction factor determined by the beam shape and the depth of bleaching, with a value of 0.88.³⁸

Membrane hole identification

To identify membrane holes, the threshold value was set by using the signal/noise ratio option in NIS-Elements BR software. The setting used was the result of subtracting 6 of standard deviations from average fluorescence intensity of the bilayer areas between holes. This threshold was automatically applied for analysis of the areas and the sizes of membrane holes.

Results and discussion

PPN induces reorganization of POPC SLBs

To explore the structural effects of PPN on SLBs, incubation experiments were carried out in PDMS wells. The work was

performed with 10 mM HEPES buffer solution containing 150 mM NaCl at pH 7.4 unless otherwise specified. The lateral mobility of SLBs at room temperature was confirmed by FRAP measurements (data not shown).

Phosphatidylcholine (PC) is one of the essential components of all mammalian cell types and subcellular organelles. It accounts for more than 50% of total cellular phospholipids.⁴² In an initial series of experiments, SLBs containing 99.5 mol% POPC and 0.5 mol% Liss-Rhod-DOPE were used. Time-lapse fluorescence images obtained after incubation of PPN with SLBs are shown in Fig. 2. As can be seen, bright fluorescent spots started to decorate on the surface of homogeneous bilayers immediately (within few seconds) after PPN addition (Fig. 2b). Fluorescence intensity of the bright spots is roughly double that of the surrounding area, suggesting an uneven distribution of the dye in the bilayer. According to the curvature preference of Liss-Rhod-DOPE,⁴³ it can be inferred that the bright spots are areas of high membrane curvature induced by PPN. Strand like protrusions that we term lipid tubules then grew from the bright spots in several minutes (Fig. 2c). These lipid tubules retain a point of association to the bilayer surface and may extend up to hundreds of micrometers at higher concentrations of PPN (15 mM–40 mM). The floating ends of the lipid tubules possess high mobility and many of them were consequently out of focus (see movies S1 and S2†).

Curiously, over the course of minutes, numerous lipid tubules were observed to shrink in length followed by the formation of large circular patches (Fig. 2d–f). These patches may gradually increase in size and eventually disappear from bilayer surface in a short time (Fig. 2h). Fluorescence characteristics of the patch were then investigated. Line scan of the image shows that fluorescence profile of the patch approaches a Gaussian distribution, indicating higher curvature in the center of the patch (Fig. 3). Moreover, the fluorescence intensity of the patch levels off at first and then decreased sharply at the same time with the disappearance of the patch (Fig. 4). Besides, FRAP experiments revealed that lipids maintained lateral mobility after disappearance of the patch. The diffusion coefficient was consistent before ($0.786 \pm 0.022 \mu\text{m}^2 \text{s}^{-1}$) and after ($0.979 \pm 0.031 \mu\text{m}^2 \text{s}^{-1}$) PPN treatment. The data are consistent with the literature value for POPC SLB doped with 1 mol% of fluorescent Texas Red DHPE ($0.8\text{--}1.2 \mu\text{m}^2 \text{s}^{-1}$).⁴⁴ Moreover, the mobile fraction for the SLB is $93 \pm 1\%$, confirming the two-dimensional fluidity of the bilayer that enables the recovery of fluorescence intensity after photobleaching.

These observations, taken together, indicate a transition from high-curvature structures (*i.e.*, tubules) to low-curvature structures (*i.e.*, patches) and ultimately, to a flat bilayer. We therefore propose that the patches are hemispherical caps which caused by tubule collapse,^{45,46} rather than spherical buds composed of entangled tubules.⁴⁷ In addition to the tubules and patches described above, the floating fluorescent materials across the field of view were observed (Fig. 2g), suggesting that some local removal of bilayer material could occur during PPN incubation.

Additional experiments revealed that formation of these surface features was, at least partially reversible upon the






Fig. 2 Time-lapse fluorescence micrographs of structural reformation in POPC SLBs treated with 20 mM PPN. Each image represents the SLB after PPN incubation for: (a) 0 min, (b) 0.12 min, (c) 5 min, (d) 60 min, (e) 80 min, (f) 110 min, (g) 120 min, and (h) 140 min. The micrographs were observed at 40 \times magnification. Scale bar: 20 μ m.




Fig. 3 (a) A patch observed in POPC SLBs treated with 20 mM PPN. The red arrow traces the fluorescence intensity profile across the centre of the patch, shown in (b). The micrographs were observed at 40 \times magnification. Scale bar: 10 μ m.




Fig. 4 Fluorescence intensity of the patch changes with time after introduction of 20 mM PPN. The red arrows in the sequential images point to the patch. The fluorescence images were observed at 40 \times magnification. Scale bar: 10 μ m.

removal of the substances loosely attached to the surface. Fig. 5 shows images of SLBs after PPN treatment followed by thoroughly rinsing with HEPES buffer solution. As can be seen, SLBs treated with lower concentrations of PPN (<5 mM) could recover to be uniform after surface washing (Fig. 5a and b). However, darker areas of decreased fluorescence were observed on the SLBs treated with higher concentrations of PPN (5 mM–40 mM) (Fig. 5c–f). The size of the darker areas varied from <1 μ m² up to 14.5 μ m² and the size distribution gradually shifted to larger area with increasing concentrations of the drug (Fig. 6). FRAP experiments showed that the lipids had lateral mobility within the remaining membrane, with dark areas unperturbed (Fig. 7). This supports the notion of static holes within an otherwise

continuous fluid lipid bilayers.^{33,48} Therefore, the dark areas are holes formed in the bilayer due to partial solubilization of the bilayer induced by PPN. The observation of these darker areas is consistent with our observations, as discussed above, of fluorescent material floating across the field of view when PPN was introduced to the bilayers.

Analogous phenomena have been observed both in modeling experiments and biological processes such as endocytosis, tabulation, and vesiculation.^{49–52} Generally, the transition of a relative planar structure to a more curved structure may arise from the adsorption of various substances, such as macromolecules, ions, as well as small molecules, which differ in their sizes and properties.^{43,53–59} It has been reported that amphiphile-induced bilayer remodeling are strongly correlated






Fig. 5 Hole formation in POPC SLBs after PPN (>5 mM) treatment and washing. (a–f) Fluorescence images showing SLBs after treatment with different concentrations of PPN followed by washing the surface. The fluorescence images were observed at 40 \times magnification. Scale bar: 20 μ m.




Fig. 6 Histogram of the hole size on the surface of POPC SLBs after 1 h incubation with different concentrations of PPN: (a) 10 mM, (b) 20 mM, (c) 30 mM, and (d) 40 mM. The y-axis shows the percentage of average count numbers from different bilayers. The error bars represent the standard deviations obtained by averaging at least 4 independent measurements.

to the thermodynamic barrier of the interacting amphiphile to translocation across the bilayer.^{45,46,60} Specifically, when amphiphiles are incubated with a bilayer, they may impart an asymmetric, lateral stress on the outer leaflet that is not immediately matched by the inner leaflet. If the bilayer area is fixed, as in the current SLB experiment, the PPN-induced asymmetrical stress would overwhelm the adhesive strength of the underlying solid support, leading to the formation of regions with high curvature (such as lipid tubules).⁴⁵ However, if the translocation, *i.e.*, “flip-flop”, of amphiphiles across the bilayer occurs, the asymmetrical stress would be expected to be relieved, leading to the decreasing of curvature, *i.e.* the formation of lower-curvature structures (such as hemispherical caps) or restoration of planar bilayers. Therefore, the shrinking and disappearance of tubules and caps observed in our experiments can be interpreted in terms of accumulation and relief of asymmetric stresses in the inner and outer leaflets of a bilayer upon the insertion and translocation of PPN in ways that are similar to previous experiments using other amphiphiles. It should be noted that desorption of PPN from the bilayer upon washing with buffer or bilayer dissolution may also equilibrate stresses in the bilayer and promotes a transition from high-curvature tubules to low-curvature hemispherical caps and






Fig. 7 FRAP experiments of POPC SLBs treated with 20 mM PPN followed by washing the surface. The red line is single exponential fits to the data. The error bars represent the standard deviations obtained by averaging at least 4 independent measurements.

ultimately, in the limit of complete PPN desorption, to a flat bilayer.

Moreover, as a short molecule whose non-polar moieties are not as long as the hydrocarbon chains of phospholipids, PPN may act as a wedge in the membrane, causing energetically unfavorable voids between hydrocarbon chains in the bilayer interior.⁶¹ Thus, bending of membrane is energetically favored to eliminate the voids. Indeed, due to the asymmetric distribution of PPN, the bilayer will prefer to curve toward the inserted PPN, expanding the upper leaflet with the larger coverage of drug molecules and compressing the lower leaflet with less drug molecules.⁵⁸

Besides, the observation of substantial disruption and dissolution of bilayers may be related to the detergent-like characteristic of PPN.^{4,8} Although the PPN concentration used in this study is lower than its cmc (~ 108 mM),⁶² local concentration of the drug in the bilayer may be much higher than that in the bulk aqueous phase, which possibly promotes the formation of lipid-drug mixed micelles that may consequently shed from the bilayer into the bulk solution. Indeed, tubulation expands lipid headgroup-headgroup spacing in the upper leaflet of bilayer which in turn promotes accumulation of PPN in the tubules compared with the surrounding planar bilayers. Actually, the onset of micellization occurs at the concentration lower than the cmc of pure detergents has been reported elsewhere.⁶³

Kinetics of interaction between PPN and POPC SLBs

To further explore the intrinsic mechanism of interaction between PPN and lipid bilayers, microfluidic experiments were conducted. HEPES buffer solution was flowed into the microfluidic channels in which lipid bilayers were formed. After fluorescence intensity reaches equilibrium, PPN (0–40 mM) was introduced into the channels. Time-lapse images were acquired every 5 min and fluorescence stabilization took about 1 h at the lowest drug concentration. Buffer solution was then introduced to rinse away PPN and any other loosely attached lipid materials. The individual fluorescence line scans were then exerted. As can be seen in Fig. 8, the fluorescence intensity of lipid bilayers decreased with increasing concentration of PPN. At the highest concentration of PPN employed, 40 mM, the fluorescence intensity decreased to 70% of its initial level. This attenuation in the fluorescence intensity confirms the PPN-




Fig. 8 Fluorescence images from microfluidic devices with POPC SLBs before (a and d) and after (b and e) introduction of PPN. The blue and red lines represent the regions used to obtain the line profiles shown in (c and f).



induced disruption of SLBs, *i.e.*, the release of bilayer lipids into the medium.

By plotting the fluorescence intensity change as a function of drug concentration, the profile of PPN-bilayer interaction can be obtained (Fig. 9). The *y*-axis represents change of fluorescence intensity at equilibrium, ΔF , which is calculated as $(F/F_0 - 1)$. Here, F corresponds to the fluorescence intensity of the bilayer at a specific concentration of PPN in the bulk solution, whereas F_0 is the fluorescence intensity of the bilayer in pure buffer. Significantly, the interaction profile showed a complex shape, consisting of three distinct steps, corresponding to three separate concentration ranges (0–10 mM, 10–30 mM and 30–40 mM). The interaction profiles for step 1 and step 2 fit well to a Langmuir isotherm (eqn (5)):

$$\Delta F = \Delta F_{\max} \frac{[\text{PPN}]}{K_d + [\text{PPN}]} \quad (5)$$

wherein $[\text{PPN}]$ is the bulk concentration of PPN and ΔF_{\max} is a constant corresponding to the maximum relative fluorescence intensity change at the highest concentration of PPN solution.⁶⁴ The fit yields K_{d1} of 1.40 ± 0.12 mM for step 1 and K_{d2} of 28.60 ± 7.71 mM for step 2. K_{d1} corresponds well to the value found by isothermal titration calorimetry (ITC) combined with zeta potential measurements for PPN binding to POPC liposomes at 298 K,²⁹ but a value corresponding to the second step has not been reported previously. Moreover, the fluorescence intensity increased in a linear fashion in step 3, suggesting unsaturable interaction of PPN and lipid bilayer at high PPN concentrations.

Our current data showing a three-step interaction profile of PPN-bilayer is consistent with the notion that binding of amphiphiles with lipid membranes undergoes a consecutive stepwise process.^{53,65,66} Generally, the first binding step was dominated by electrostatics, which involves the interaction between the amine group of PPN and the carbonyl group of

phospholipids, as well as the interaction between the hydroxyl group of PPN and the carbonyl group of phospholipids.⁶¹ This can be confirmed by an additional experiment using higher buffer concentrations. Presumably, the increase in the ionic strength of the solution leads to the decrease in Debye length which, in turn, enlarge the electrostatic screening and therefore the drug–membrane interactions should weaken.^{67,68} Herein, 50 mM HEPES buffer solution was utilized and the assays were otherwise carried out under the same conditions as those in Fig. 9. The resulted binding curve was provided in Fig. 10. As can be seen, increasing buffer concentration decreased the affinity between PPN and the bilayers by approximately 3-fold ($K_d = 3.68 \pm 0.36$ mM), verifying that the first step of PPN/membrane binding is mainly electrostatic. In fact, there is a competition between strong electrostatic interactions and van der Waals interactions between the naphthalene ring of PPN and non-polar lipid tails.⁶¹ Although electrostatic interactions prevail in the first step, the adsorption of PPN to the bilayer may gradually increase the fluidity of the lipids, lower its area stretch modulus and decrease the interfacial potential, which helps to facilitate the second step, in which hydrophobic insertion and deeper penetration of the drug into the lipid bilayer occurs.^{33,69} Moreover, PPN not only intercalated into lipid bilayer or expanded the membrane area, but also disrupt the packing of PC lipids.⁶¹ In that case, the third step associated with membrane disruption and hole formation can be considered a direct consequence of PPN binding.^{62,70} These results are in agreement with the observation obtained from the PDMS well experiments. It should be noted that the attenuation in the fluorescence intensity in the first and the second step, suggesting PPN-containing bilayer is likely to be unstable even at lower concentrations, although major damage or hole formation on the membrane is not detectable in the incubation experiments.

The dissociation constants of PPN–membrane interaction were compared with those for the interaction of other small drugs, including ibuprofen (IBU) and tetracaine (TTC), with




Fig. 9 Binding profile of POPC SLBs with PPN concentration of 0–40 mM. The data (step 1 and 2) can be fit well to a Langmuir isotherm. At high concentrations (>30 mM), the data (step 3) can be fit to a straight line ($r^2 = 0.995$). The error bars represent the standard deviations obtained by averaging at least 4 independent measurements.




Fig. 10 Binding curve of PPN (0–10 mM) and POPC lipid bilayer in 50 mM HEPES buffer at pH 7.4. The error bars represent the standard deviations obtained by averaging at least 4 independent measurements.



lipid membranes.^{33,71} As expected, the membrane affinities of the drug are substantially different, although they have similar amphiphilic properties and similar multiple consecutive binding steps with lipid membranes. The dissociation constant values of K_d follow the order: PPN > TTC > IBU. This is consistent with the notion that the interaction of a bioactive compound across lipid membranes is correlated with its lipophilicity.^{21,72} Supposedly, the drugs with higher lipophilicity have relative stronger ability to interact with lipid membranes. In the current study, the weaker membrane affinity of PPN could be due to the fact that PPN has relatively lower lipophilicity as compared to TTC and IBU.

Interaction between PPN and binary mixed SLBs

In the next set of experiments, cholesterol, uncharged POPE, negatively charged POPG and POPS was respectively introduced into POPC SLBs and tested for PPN interactions. The buffer for POPS contained 0.8 mM EDTA due to the potential quenching ability of trace concentrations of divalent metal ions such as Cu^{2+} .⁶⁴ The experimental conditions were otherwise identical to those in POPC experiments.

A representative image from flow cell experiment after incubation with 15 mM PPN is shown in Fig. 11. As can be seen, the formation of surface features considerably differs upon

adding other membrane lipids into POPC SLBs, suggesting PPN/SLB interaction is significantly dependent on membrane composition. Binding profiles of PPN to bilayers are plotted in Fig. 12 and the extracted apparent K_d values are provided in Table 1.

Cholesterol is an essential structural component of mammalian cells, varying significantly in concentration in the membranes of different organelles. It affects the structure and dynamics of membranes by interacting with lipids and membrane-related proteins.^{73–75} To test the effect of cholesterol on PPN/bilayer interaction, 20 mol% cholesterol was introduced into POPC SLBs. As is shown in Fig. 12a and Table 1, the K_{d1} value for the first binding step decreased approximately 4-fold (from 1.40 ± 0.12 mM to 0.35 ± 0.05 mM) compared to pure POPC bilayer membrane. This is likely the consequence of hydrogen bonding between cholesterol and PPN. Several studies have demonstrated the ability of cholesterol to form hydrogen bond with various small molecules.^{76–79} Liang Chen *et al.* demonstrated hydrogen bond formation between hydroxyl hydrogen on the A-ring of epicatechin and hydroxyl oxygen of cholesterol.⁷⁶ Yuan *et al.* proposed hydrogen bond formation between POPC and cholesterol between either the hydroxyl and phosphate or hydroxyl and carbonyl.⁷⁷ By analogy, a hydrogen bond is likely to form between the amine groups on PPN and the hydroxyl from cholesterol. In the second binding step, K_{d2}




Fig. 11 Fluorescence images of various SLBs treated with 20 mM PPN followed by washing the surface. (a–e) Each column represents the SLB containing a specific lipid composition. The fluorescence images were observed at 40 \times magnification. Scale bar: 20 μm .






Fig. 12 Binding profiles of PPN to SLBs with different lipid compositions. All the membranes contained 0.5 mol% Liss-Rhod-DOPE and 79.5 mol% POPC: (a) 20 mol% cholesterol; (b) 20 mol% POPE; (c) 20 mol% POPG; (d) 20 mol% POPS. The red curve represents the best fit for step 1, 2 and 3. The error bars represent the standard deviations obtained by averaging at least 4 independent measurements.

decreased approximately 2-fold (from 28.60 ± 7.71 mM to 13.45 ± 1.50 mM) compared with pure POPC bilayer. This strengthening of the PPN/SLB interaction is in agreement with the notion that cholesterol can induce expansion of lipid–lipid distance that facilitates insertion of various amphiphilic molecules into the bilayer.^{77,80–83} This observation therefore confirms that the second binding step is dominated by hydrophobic interaction. Moreover, previous studies have shown that cholesterol generates intrinsic negative curvature in lipid bilayers and lower the formation energy of highly curved membrane structures such as lipid stalks that are proposed as lipid intermediates in membrane fusion. Cholesterol thereby has the potential of promoting membrane fusion.^{84–89} As such, it is

reasonable that cholesterol helps formation of lipid tubules, hence facilitating membrane disruption and hole formation.

Phosphatidylethanolamine (PE) is the second most abundant phospholipid in eukaryotic cells membranes, accounting for 20–50 mol% of total phospholipid, which can comprise up to 45 mol% phospholipids in the brain.^{90,91} Therefore, it is of great importance to understand the influence of PE on drug/membrane interaction. For the current experiment, POPE was used since it has the same tail group as POPC. The binding constants K_{d1} and K_{d2} were both significantly decreased for SLBs containing 20% POPE compared to pure POPC bilayers (Fig. 12b and Table 1). This increase of PPN affinity with bilayer is probably due to the formation of hydrogen bonding between

Table 1 Dissociation constants (K_d) of PPN–membrane interactions with various membrane compositions

	POPC	POPC + 20% cholesterol	POPC + 20% POPE	POPC + 20% POPG	POPC + 20% POPS
K_{d1} (mM)	1.40 ± 0.12	0.35 ± 0.05	0.03 ± 0.004	0.49 ± 0.10	0.52 ± 0.13
K_{d2} (mM)	28.60 ± 7.71	13.45 ± 1.50	1.42 ± 0.20	20.00 ± 5.86	26.02 ± 7.38






Fig. 13 Schematic illustration of the structural remodeling of POPC bilayers induced by the addition of propranolol.

POPE lipids and PPN. There has been evidence that the amine group of PPN interacts with carbonyl group of the lipid acyl chains; on average, amino group have two hydrogen bonds that are provided to carbonyl oxygen atoms.⁶¹ Also, a hydrogen bond is likely to form between the hydroxyl group of PPN and the phosphate group of the lipids and generally one hydrogen bond is donated by the hydroxyl group to phosphates.^{61,92} Moreover, compared to most other cylindrical-shaped phospholipids such as PC, PE lipids adopt a conical shape due to the relative volume difference between its small ethanolamine head group and long, unsaturated acyl chains.⁹³ PE thereby induces negative spontaneous curvature in membranes, which is reported to make the planar bilayers unstable.³¹ In fact, when PPN inserts into the POPE-containing bilayers, it acts as a wedge, relieving the lipid packing constraints caused by the presence of POPE.⁹⁴ Thus, it is energetically favorable for PPN to fill up the POPE-induced voids between phospholipid headgroups.

Negatively charged lipids are integral components of eukaryotic cell membranes and organelles. Although they are not as abundant as PE or cholesterol in biological membranes, negatively charged lipids play essential roles in biological processes, such as apoptosis and cell signaling.^{95–99} Herein, two negatively charged lipids, POPS and POPG with concentration of 20 mol%, are introduced into POPC SLBs. As can be seen in Fig. 12c, d and Table 1, the influence of POPS and POPG on the K_{d1} and K_{d2} values is essentially identical, suggesting the effect should be electrostatic rather than chemically specific. Compared with pure POPC SLBs, the first binding step was significantly strengthened by the addition of POPS and POPG. This is expected since the incorporation of any of these two lipids into the bilayer will make the surface potential more negative and in turn promotes the electrostatic interactions between the positively charged PPN and the bilayer.¹⁰⁰ Moreover, it was observed that the insertion ability of PPN into the bilayer was identical between the negatively charged bilayers and pure POPC SLBs. Indeed, as cylindrical lipids, with hydrophobic tails and hydrophilic heads of similar cross section PS and PG are likely to form lamellar bilayers lacking curvature as the size of polar head groups rather than the acyl chain determines the intrinsic shape of the lipid.⁸⁴ Therefore, it is logical that PS and PG do not affect the insertion of PPN into the bilayer as they do not influence membrane curvature.

Conclusions

The work reported here demonstrates that PPN, because of its structure and of the presence of charged heads, may interact with lipid membranes to induce large-scale membrane remodeling, *i.e.*, the formation of three-dimensional surface structures with high curvature followed by membrane disruption and solubilization (Fig. 13). Moreover, the kinetic analysis revealed that PPN has concentration-dependent binding behaviour with lipid membranes. The interaction between PPN and lipid membranes shows three consecutive steps, involving the initial electrostatically adsorption onto the bilayer surface, the consequent hydrophobic insertion of the drug, and the final membrane solubilization. The profiles of the first two steps fit well to a Langmuir isotherm, while the final step is associated with the detergent characteristic of PPN, *i.e.*, unsaturable interaction that induces membrane solubilization. Besides, the affinity between PPN and lipid bilayer could be significantly modulated by incorporating other lipids into POPC SLBs, indicating the dependence of membrane physical properties on drug–membrane interactions.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We are grateful to Danling Cheng at the Shanghai University of Engineering Science for technical assistance with small unilamellar vesicles preparation and supported lipid bilayer formation.

Notes and references

- 1 H. Yin and A. D. Flynn, *Annu. Rev. Biomed. Eng.*, 2016, **18**, 51.
- 2 M. Lucio, J. Lima and S. Reis, *Curr. Med. Chem.*, 2010, **17**, 1795–1809.
- 3 M. J. Saxton, *Biophys. J.*, 1987, **52**, 989–997.
- 4 J. K. Seydel, E. A. Coats, H. P. Cordes and M. Wiese, *Arch. Pharm.*, 1994, **327**, 601–610.



- 5 G. P. van Balen, C. a. M. Martinet, G. Caron, G. Bouchard, M. Reist, P. A. Carrupt, R. Fruttero, A. Gasco and B. Testa, *Med. Res. Rev.*, 2004, **24**, 299–324.
- 6 M. R. Bristow, *Circulation*, 2000, **101**, 558–569.
- 7 R. Bisby, S. Botchway, A. Crisostomo, J. Karolin, A. Parker and L. Schröder, *Spectroscopy*, 2010, **24**, 137–142.
- 8 E. K. Jackson and W. B. Campbell, *Hypertension*, 1981, **3**, 23–33.
- 9 R. Grewal and C. Kaul, *Br. J. Pharmacol.*, 1970, **38**, 771.
- 10 K. Azizi and M. G. Koli, *J. Mol. Graphics Modell.*, 2016, **64**, 153–164.
- 11 G. Först, L. Cwiklik, P. Jurkiewicz, R. Schubert and M. Hof, *Eur. J. Pharm. Biopharm.*, 2014, **87**, 559–569.
- 12 K. W. Surewicz, I. Fijałkowska and W. Leyko, *Biochem. Pharmacol.*, 1981, **30**, 839–842.
- 13 D. V. Godin, T. W. Ng and J. M. Tucek, *Biochim. Biophys. Acta, Biomembr.*, 1976, **436**, 757–773.
- 14 A. Ekman, V. Manninen and S. Salminen, *Acta Physiol. Scand.*, 1969, **75**, 333–344.
- 15 W. K. Surewicz and W. Leyko, *Biochim. Biophys. Acta*, 1981, **643**, 387–397.
- 16 D. V. Godin, T. W. Ng and J. M. Tucek, *Biochim. Biophys. Acta*, 1976, **436**, 757–773.
- 17 H. Porzig, *J. Physiol.*, 1975, **249**, 27–49.
- 18 H. Komai and H. A. Berkoff, *Biochem. Pharmacol.*, 1979, **28**, 1501–1504.
- 19 C. Pereira-Leite, C. Carneiro, J. X. Soares, C. Afonso, C. Nunes, M. Lúcio and S. Reis, *Eur. J. Pharm. Biopharm.*, 2013, **84**, 183–191.
- 20 G. Mangiapia, M. Gvaramia, L. Kuhrts, J. Teixeira, A. Koutsiousbas, O. Soltwedel and H. Frielinghaus, *Phys. Chem. Chem. Phys.*, 2017, **19**, 32057–32071.
- 21 K. Kannisto, L. Murtoimäki and T. Viitala, *Colloids Surf., B*, 2011, **86**, 298–304.
- 22 L. Li, L. Yu, H. He, L. Wei, Z. Xu, L. Zhao, Y. Sun, B. Zhang, Y. Liu and R. He, *Frontiers in Pediatrics*, 2022, **10**, 849496.
- 23 J. Wójcicki, V. Sulzyc-Bielicka, J. Kutrzeba, B. Gawrońska-Szklarz, M. Drożdżik and Z. Sterna, *J. Clin. Pharmacol.*, 1999, **39**, 826–833.
- 24 M. N. Kalam, M. F. Rasool, A. U. Rehman and N. Ahmed, *Curr. Drug Metab.*, 2020, **21**, 89–105.
- 25 R. Bisby, A. Crisostomo, S. Botchway, A. Parker and S. Watts, *Central Laser Facility Annual Report*, 2009, pp. 147–148.
- 26 M. Mizogami, K. Takakura and H. Tsuchiya, *Eur. J. Anaesthesiol.*, 2010, **27**, 829–834.
- 27 G. Castronuovo and M. Niccoli, *Bioorg. Med. Chem.*, 2006, **14**, 3883–3887.
- 28 S. De Carlo, H. Fiaux and C. A. Marca-Martinet, *J. Liposome Res.*, 2004, **14**, 61–76.
- 29 M. Ikonen, L. Murtoimäki and K. Kontturi, *Colloids Surf., B*, 2010, **78**, 275–282.
- 30 H. Li, T. Zhao and Z. Sun, *Rev. Anal. Chem.*, 2017, **37**, 20170012.
- 31 A. M. Sendecki, M. F. Poyton, A. J. Baxter, T. Yang and P. S. Cremer, *Langmuir*, 2017, **33**, 13423–13429.
- 32 W. K. Surewicz and W. Leyko, *Biochim. Biophys. Acta, Biomembr.*, 1981, **643**, 387–397.
- 33 S. Sun, A. M. Sendecki, S. Pullanchery, D. Huang, T. Yang and P. S. Cremer, *Langmuir*, 2018, **34**, 10782–10792.
- 34 H. Jung, A. D. Robison and P. S. Cremer, *J. Am. Chem. Soc.*, 2009, **131**, 1006–1014.
- 35 M. F. Poyton, A. M. Sendecki, X. Cong and P. S. Cremer, *J. Am. Chem. Soc.*, 2016, **138**, 1584–1590.
- 36 A. A. Brian and H. M. Mcconnell, *Proc. Natl. Acad. Sci. U. S. A.*, 1984, **81**, 6159–6163.
- 37 P. S. Cremer and S. G. Boxer, *J. Phys. Chem. B*, 1999, **103**, 2554–2559.
- 38 D. Axelrod, D. E. Koppel, J. Schlessinger, E. Elson and W. W. Webb, *Biophys. J.*, 1976, **16**, 1055–1069.
- 39 M. D. Soumpasis, *Biophys. J.*, 1983, **41**, 95–97.
- 40 R. Richter, A. Mukhopadhyay and A. Brisson, *Biophys. J.*, 2003, **85**, 3035–3047.
- 41 D. Shengjuler, S. Sun, P. S. Cremer and C. E. Cameron, *J. Visualized Exp.*, 2017, e55869.
- 42 J. N. van der Veen, J. P. Kennelly, S. Wan, J. E. Vance, D. E. Vance and R. L. Jacobs, *Biochim. Biophys. Acta, Biomembr.*, 2017, **1859**, 1558–1572.
- 43 P. G. Adams, L. Lamoureux, K. L. Swingle, H. Mukundan and G. A. Montañó, *Biophys. J.*, 2014, **106**, 2395–2407.
- 44 A. M. Brozell, M. A. Muha, B. Sani and A. N. Parikh, *J. Am. Chem. Soc.*, 2006, **128**, 62–63.
- 45 M. Staykova, M. Arroyo, M. Rahimi and H. A. Stone, *Phys. Rev. Lett.*, 2013, **110**, 028101.
- 46 C. G. Gahan, S. J. Patel, L. M. Chen, D. E. Manson, Z. J. Ehmer, H. E. Blackwell, R. C. Van Lehn and D. M. Lynn, *Langmuir*, 2021, **37**, 9120–9136.
- 47 B. K. Yoon, J. A. Jackman, M. C. Kim and N.-J. Cho, *Langmuir*, 2015, **31**, 10223–10232.
- 48 P. Rangamani, K. K. Mandadap and G. Oster, *Biophys. J.*, 2014, **107**, 751–762.
- 49 J. C. Stachowiak, C. C. Hayden and S. Whitesides, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 7781–7786.
- 50 N. Wang, L. D. Clark, Y. Gao, M. M. Kozlov, T. Shemesh and T. A. Rapoport, *Nat. Commun.*, 2021, **12**, 1–15.
- 51 S. Jones, A. Huynh, Y. Gao and Y. Yu, *Mater. Chem. Front.*, 2018, **2**, 603–608.
- 52 S. Zuraw-Weston, D. A. Wood, I. K. Torres, Y. Lee, L.-S. Wang, Z. Jiang, G. R. Lázaro, S. Wang, A. A. Rodal and M. F. Hagan, *Nanoscale*, 2019, **11**, 18464–18474.
- 53 S. Hu, T. Zhao, H. Li, D. Cheng and Z. Sun, *Biochim. Biophys. Acta, Biomembr.*, 2020, **1862**, 183351.
- 54 R. Lipowsky, *Faraday Discuss.*, 2012, **161**, 305–331.
- 55 V. Nikolov, R. Lipowsky and R. Dimova, *Biophys. J.*, 2007, **92**, 4356–4368.
- 56 H. T. McMahon and J. L. Gallop, *Nature*, 2005, **438**, 590–596.
- 57 J. Zimmerberg and M. M. Kozlov, *Nat. Rev. Mol. Cell Biol.*, 2006, **7**, 9–19.
- 58 R. Lipowsky and H.-G. Döbereiner, *Europhys. Lett.*, 1998, **43**, 219.
- 59 R. Lipowsky, *Europhys. Lett.*, 1995, **30**, 197.
- 60 H. Heerklotz, *Q. Rev. Biophys.*, 2008, **41**, 205–264.



- 61 G. Först, L. Cwiklik, P. Jurkiewicz, R. Schubert and M. Hof, *Eur. J. Pharm. Biopharm.*, 2014, **87**, 559–569.
- 62 D. Attwood and S. Agarwal, *J. Pharm. Pharmacol.*, 1979, **31**, 392–395.
- 63 D. Lichtenberg, H. Ahyayauch and F. M. Goñi, *Biophys. J.*, 2013, **105**, 289–299.
- 64 D. Huang, T. Zhao, W. Xu, T. Yang and P. S. Cremer, *Anal. Chem.*, 2013, **85**, 10240–10248.
- 65 N. B. Last and A. D. Miranker, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 6382–6387.
- 66 H. W. Huang, *Biochemistry*, 2000, **39**, 8347–8352.
- 67 N. Ac, *Annu. Rev. Biophys. Biomol. Struct.*, 1993, **22**, 1–25.
- 68 S. Li and N. Malmstadt, *Soft Matter*, 2013, **9**, 4969–4976.
- 69 L. Picas, F. Rico and S. Scheuring, *Biophys. J.*, 2012, **102**, L01–L03.
- 70 H. Porzig, *J. Physiol.*, 1975, **249**, 27–49.
- 71 S. Hu, T. Zhao, H. Li, D. Cheng and Z. Sun, *Biochim. Biophys. Acta, Biomembr.*, 2020, **1862**, 183351.
- 72 T. T. Nguyen, K. Rembert and J. C. Conboy, *J. Am. Chem. Soc.*, 2009, **131**, 1401–1403.
- 73 J. L. Pike, *J. Lipid Res.*, 2008, **50**, S323–S328.
- 74 R. M. Epand, *Prog. Lipid Res.*, 2006, **45**, 279–294.
- 75 J. Fantini, *Curr. Med. Chem.*, 2007, **14**, 2911–2917.
- 76 K. Zheng, K. Guo, J. Xu, W. Liu and L. Chen, *Open Chem.*, 2020, **18**, 357–368.
- 77 J. Yuan and F. Meng, *J. Mol. Model.*, 2021, **27**, 1–10.
- 78 M. Markiewicz and M. Pasenkiewicz-Gierula, *Langmuir*, 2011, **27**, 6950–6961.
- 79 T. E. Oliver, S. Piantavigna, P. C. Andrews, S. A. Holt and C. T. Dillon, *Langmuir*, 2021, **37**, 1337–1352.
- 80 M. Egashira, G. Gorbenko, M. Tanaka, H. Saito, J. Molotkovsky, M. Nakano and T. Handa, *Biochemistry*, 2002, **41**, 4165–4172.
- 81 A. Jp, B. Ad and B. Ls, *Biochim. Biophys. Acta, Biomembr.*, 2019, **1861**, 201–209.
- 82 A. Martyna, B. Bahsoun, J. J. Madsen, F. S. J. Jackson, M. D. Badham, G. A. Voth and J. S. Rossman, *J. Phys. Chem. B*, 2020, **124**, 6738–6747.
- 83 A. Khajeh and H. Modarress, *Biochim. Biophys. Acta, Biomembr.*, 2014, **1838**, 2431–2438.
- 84 W. Wang, L. Yang and H. W. Huang, *Biophys. J.*, 2007, **92**, 2819–2830.
- 85 A. Ivankin, I. Kuzmenko and D. Gidalevitz, *Phys. Rev. Lett.*, 2012, **102**, 293a.
- 86 Y. Kozlovsky and M. M. Kozlov, *Biophys. J.*, 2002, **82**, 882–895.
- 87 V. S. Markin and J. P. Albanesi, *Biophys. J.*, 2002, **82**, 693–712.
- 88 L. V. Chernomordik and M. M. Kozlov, *Cell*, 2005, **123**, 375–382.
- 89 L. V. Chernomordik and M. M. Kozlov, *Annu. Rev. Biochem.*, 2003, **72**, 175–207.
- 90 J. E. Vance, *J. Lipid Res.*, 2008, **49**, 1377–1387.
- 91 N. R. Deleault, J. R. Piro, D. J. Walsh, F. Wang, J. Ma, J. C. Geoghegan and S. Supattapone, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, 8546–8551.
- 92 C. D. Graaf, C. Oostenbrink, P. H. J. Keizers, B. M. A. V. Vugt-Lussenburg and N. P. E. Vermeulen, *Eur. Biophys. J.*, 2007, **36**, 589–599.
- 93 N. D. Ridgway, *Biochemistry of Lipids Lipoproteins & Membranes*, 2016, 209–236.
- 94 A. P. Hornby and P. R. Cullis, *Biochim. Biophys. Acta*, 1981, **647**, 285–292.
- 95 D. G. Grenache and A. M. Gronowski, *Clin. Biochem.*, 2006, **39**, 1–10.
- 96 A. M. Seddon, M. Lorch, O. Ces, R. H. Templer, F. Macrae and P. J. Booth, *J. Mol. Biol.*, 2008, **380**, 548–556.
- 97 Y. Ohkawa, Y. Ohmi, O. Tajima, Y. Yamauchi, K. Furukawa and K. Furukawa, *Biochem. Biophys. Res. Commun.*, 2011, **411**, 483–489.
- 98 R. K. Yu, Y. T. Tsai and T. Ariga, *Neurochem. Res.*, 2012, **37**, 1230–1244.
- 99 T. Yeung, G. E. Gilbert, J. Shi, J. Silvius, A. Kapus and S. Grinstein, *Science*, 2008, **319**, 210–213.
- 100 M. Nakagaki, I. Katoh and T. Handa, *Biochemistry*, 1981, **20**, 2208–2212.

